Serina Therapeutics announces POZ polymer license agreement with Pfizer

Serina Therapeutics, which entered a proposed merger transaction with AgeX (AGE), announced Serina has entered into a License Agreement under which Pfizer (PFE) will license, on a non-exclusive basis, Serina’s POZ polymer technology. “We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,” stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. “The license agreement represents an important milestone for Serina.”